Seres Therapeutics(MCRB) - 2024 Q4 - Earnings Call Presentation

Financial Position and Strategic Outlook - Seres Therapeutics maintains a cash runway extending into Q1 2026, supported by the VOWST asset sale which provided an upfront payment of $100 million and potential future sales-based milestones of $275 million[4][6][7][89] - The company is actively seeking a strategic partnership for its lead program, SER-155, to accelerate clinical development in allogeneic hematopoietic stem cell transplantation (allo-HSCT) and expand into additional target populations[4][78][89] - The organization has successfully streamlined operations and retired debt following the divestiture of the VOWST asset, which previously achieved FDA approval with an 88% sustained clinical response rate[5][7][89] Clinical Efficacy and SER-155 Program - SER-155 demonstrated a 77% relative risk reduction in bacterial bloodstream infections (BSIs) compared to placebo in Phase 1b clinical trials[4][37][89] - Clinical data showed a significant reduction in systemic antibiotic exposure for patients treated with SER-155, with a mean cumulative exposure of 9.2 days versus 21.1 days in the placebo group[44][45][89] - The FDA has granted Breakthrough Therapy designation to SER-155, with constructive feedback supporting a primary efficacy endpoint of BSI reduction at 30 days for the upcoming Phase 2 study[4][20][78][89] Market Opportunity and Pipeline Potential - The addressable patient population for SER-155 is significant, with approximately 40,000 annual allo-HSCT procedures worldwide and a potential 10x expansion into broader indications such as autologous HSCT and blood cancers[73][74] - Allo-HSCT procedures carry high economic burdens, with initial year-one costs of approximately $400,000 per patient, and infection-related complications adding an incremental cost of approximately $180,000 per patient[71][73] - The pipeline includes SER-147, an oral biotherapeutic in development for chronic liver disease, where approximately 50% of patients experience bacterial infections within a 6-month period[4][81][89]